---

• n  a substance that retards or stops an activity

• COX-2 inhibitors may fight cancer--or cause stroke.
• Two more COX-2 inhibitors, Arcoxia (from Merck) and Prexige (from Novartis), are awaiting FDA approval.
• COX-2 inhibitors may fight cancer--or cause stroke.

• activator

News & Articles

---

• Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
  Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.
  June 7, 2013 - Business Wire via Yahoo! Finance
• Clinical sequencing technology identifies new targets in diverse cancers
  Novel abnormalities in the FGFR gene were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs.
  June 7, 2013 - Science Daily

Quotes

---

• Arthur Koestler in SYS-CON Media
  We believe boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C,said Thomas P. Koestler , Ph.D., executive vice president and president, Schering-Plough Research Institute....
• Morrissey in MarketWatch (press release)
  XL147 is the leading class I selective PI3K inhibitor and has significant clinical and commercial potential in a variety of cancer indications,said Michael M. Morrissey, Ph.D., president of research and development at Exelixis. "The...